Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)

Bladder

Bladder
N/A
Arnold, Shanna
VICCURO1322

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Bladder

This is a Phase II, open-label, single-arm, multicenter study of intravesical BCG plus ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC). All patients treated in the study will receive via a urinary catheter in the bladder, BCG plus ALT-803 weekly for 6 consecutive weeks (initial induction treatment period). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. The study duration is 24 months.
Bladder
II
Chang, Sam
NCT03022825
VICCURO1784


Early Palliative Care in Improving Recovery and Quality of Life in Patients with Cancer Undergoing Abdominal Surgery, the SCOPE Trial

Multiple Cancer Types

This trial studies early palliative care in improving recovery and quality of life in patients with cancer undergoing abdominal surgery. Frequently people diagnosed with cancer experience physical and emotional symptoms during the course of their disease. Introduction to a team of clinicians that specialize in the lessening of many of these distressing symptoms may improve overall care. This team of clinicians is called the palliative care team and they focus on ways to improve pain and other symptom management (i.e. shortness of breath, fatigue, anxiety, etc.) and to assist patients and their families in coping with the emotional, social, and spiritual issues associated with a cancer diagnosis. This study is being done to see if receiving palliative care earlier is more useful compared to receiving palliative care late in the course of illness.
Bladder, Colon, Gastrointestinal, Gynecologic, Liver, Ovarian, Pancreatic, Supportive Care, Urologic
N/A
Shinall, Ricky
NCT03436290
VICCSUPP1971

The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study.

Bladder

Bladder
N/A
Scarpato, Kristen
NCT03933826
VICCURO19105

A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Bladder

The primary objective of this study is to compare MK-6482 to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that MK-6482 is superior to everolimus with respect to PFS and OS.
Bladder
III
Beckermann, Kathryn
NCT04195750
VICCURO19114

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: